诺和诺德CagriSema在3期糖尿病研究中优于司美格鲁肽。
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
生命科学资讯
生物技术与制药领域的最新动态
安捷伦将于2月25日公布2026财年第一季度财务业绩 - FinancialContent
Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25 - FinancialContent
葛兰素史克归还Wave遗传病RNA编辑技术权利
GSK gives back rights to Wave's genetic disease RNA editor
赛默飞世尔关闭富兰克林工厂，缩减马萨诸塞州员工规模。
Thermo Fisher trims Massachusetts headcount with Franklin site closure
葛兰素史克计划在美英两国裁员多达350名研发人员
GSK plans to lay off up to 350 R&D workers across US, UK
赛默飞世尔将关闭富兰克林工厂，影响多达80名员工 - 波士顿网
Thermo Fisher to close Franklin site, affecting up to 80 workers - Boston.com
新CagriSema数据显示优于司美格鲁肽的改善效果。
New CagriSema data show improvement over semaglutide
诺和联合肥胖注射剂在糖尿病试验中达到目标
Novo combination obesity shot meets goal in diabetes trial
UPC就mRNA专利战澄清PI成本明细 - Law360
UPC Clarifies PI Costs Breakdown In mRNA Fight - Law360
Thermo Fisher关闭富兰克林工厂，缩减马萨诸塞州员工规模——Fierce Pharma报道
Thermo Fisher trims Massachusetts headcount with Franklin site closure - Fierce Pharma
Thermo Fisher将关闭富兰克林工厂，裁员80人 - 波士顿环球报
Thermo Fisher to close Franklin plant, lay off 80 workers - The Boston Globe
视频：2026年英国基因组学与生物数据节——Illumina
Video: UK Festival of Genomics & Biodata 2026 - Illumina
赛诺菲从健赞继承的药物在罕见病试验中一胜一负。
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
生物制药筹集的资金
Money raised by biopharma
生物制药融资情况：2026年1月1日至30日
Biopharma money raised: Jan. 1-30, 2026
Thermo Fisher将裁员百人并关闭富兰克林工厂，高管层同时进行重组——伍斯特商业期刊报道
Thermo Fisher to lay off 100, close Franklin facility amid executive shakeup - Worcester Business Journal
葛兰素史克将Wave的AATD RNA编辑项目权利归还。
GSK returns rights to Wave's RNA editing program for AATD
早期投资者Santé Ventures筹集3.3亿美元，布局生物科技、医疗科技与数字健康领域。
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
罗氏重返RNA领域，以17亿美元收购赛诺基因项目。
Roche's return to RNA continues with $1.7B deal for Sanegene program
Optellum获英国国民医疗服务体系青睐，参与AI肺癌诊断项目。
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative